Welcome to our dedicated page for RIGEL PHARMACEUTICALS SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
Rigel Pharmaceuticals executive Raymond J. Furey reported an equity compensation award in the form of Restricted Stock Units tied to the company’s common stock. The award covers 19,497 shares, reflected as an acquisition with no cash price because it is a grant, not an open-market purchase.
These Restricted Stock Units will vest quarterly over a three-year period, with the first quarterly vesting scheduled for March 31, 2026. Following this award, Furey is shown as having 51,813 shares of common stock in direct ownership, illustrating his ongoing equity alignment with the company.
Rigel Pharmaceuticals CEO and President Raul R. Rodriguez reported an equity award on common stock. He acquired a grant of 53,915 shares through a Restricted Stock Unit award at a stated price of $0.00 per share. According to the award terms, these Restricted Stock Units will vest quarterly over three years, with the first vesting date on March 31, 2026. After this grant, Rodriguez directly owns 282,017 shares of common stock.
Rojkjaer Lisa reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC reported that EVP and Chief Medical Officer Lisa Rojkjaer received a grant of 18,894 shares of common stock in the form of Restricted Stock Units. These RSUs will vest quarterly over three years, starting with the first vesting on March 31, 2026. After this award, she is reported to beneficially own 34,853 shares of common stock directly.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno reported an equity award of company stock. He acquired 20,636 shares of common stock through a grant of restricted stock units at a stated price of $0.00 per share. Following this grant, he directly holds 76,337 common shares.
The award vests over time rather than all at once. The restricted stock units are scheduled to vest quarterly over three years, with the first quarterly vesting date on March 31, 2026. As each portion vests, the corresponding shares of common stock will be delivered to him.
Santos David A reported acquisition or exercise transactions in this Form 4 filing.
Rigel Pharmaceuticals executive David A. Santos reported an equity grant. He was awarded 19,430 shares of common stock at a price of $0.00 per share, tied to a Restricted Stock Unit award. The RSUs will vest quarterly over three years, starting on March 31, 2026, increasing his direct ownership to 62,870 shares as they vest.
Rigel Pharmaceuticals executive Dean L. Schorno reported a tax-related share disposition. As EVP & Chief Financial Officer, he had 3,546 shares of Rigel Pharmaceuticals common stock withheld on February 10, 2026 to cover tax obligations at a price of $34.62 per share.
After this tax-withholding disposition, he directly beneficially owned 55,701 shares of Rigel Pharmaceuticals common stock. The filing characterizes the transaction as payment of a tax liability by delivering securities, rather than an open-market sale.
Rigel Pharmaceuticals executive Raymond J. Furey disposed of 3,546 shares of common stock on February 10, 2026 to satisfy tax obligations. The tax-withholding disposition, reported under transaction code F at a share price of $34.62, left him holding 32,316 shares of Rigel common stock directly.
Rigel Pharmaceuticals executive David A. Santos reported a routine share disposition related to tax withholding. On 02/10/2026, 3,546 shares of common stock were disposed of at $34.62 per share to satisfy tax obligations associated with equity compensation. After this transaction, he directly owned 43,440 shares of Rigel common stock.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported an automatic share disposition related to taxes. On 02/10/2026, 7,607 shares of common stock were withheld at $34.62 per share in a transaction coded “F,” which indicates payment of tax liability by delivering securities.
After this tax-withholding disposition, Rodriguez directly owned 228,102 shares of Rigel Pharmaceuticals common stock. This filing reflects an administrative equity and tax event rather than an open-market purchase or sale.